Form D · Biotechnology
March Biosciences, Inc.
Houston, TX · CIK 0001965802
Offering snapshot reported Oct 22, 2024 · SEC filing
- Reported sold
- $22.1M Offering amount: $22.1M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 7, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2024 | Initial | $22,140,942 | No comparison | 22 | SEC filing |
| Sep 12, 2023 | Initial | $8,870 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-527549
Source: Form D, filed Oct 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sarah Hein | Director, Executive |
| Thomas Luby | Director |
| Maksim Mamonkin | Director, Executive |
| Peter Olagunju | Director |
| Joseph Petrosino | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7255 Helix Park Suite 300
Houston, TX, 77030
Houston, TX, 77030